Top

BMC Cancer

Published in:

Open Access 01-12-2016 | Research article

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China

Authors: Yi-Jun Liu, Qian Zhang, Shang-Ying Hu, Fang-Hui Zhao

Published in: BMC Cancer | Issue 1/2016

Abstract

Background

The cost-effectiveness of human papillomavirus (HPV) vaccination in women pre-sexual debut has been demonstrated in many countries. This study aimed to estimate the cost-effectiveness of a 3-dose bivalent HPV vaccination at ages 12 to 55 year in both rural and urban settings in China.

Methods

The Markov cohort model simulated the natural history of HPV infection and included the effect of screening and HPV vaccination over the lifetime of a 100,000 female cohort. Transition probabilities and utilities were obtained from published literature. Cost data were estimated by Delphi panel using healthcare payers’ perspective. Vaccine cost was assumed Hong Kong listed price. Vaccine efficacy (VE) was based on the PATRICIA trial data assuming VE irrespective of HPV type at all ages on incident HPV. Costs and outcomes were discounted at 3 %. Cervical cancer cases and incremental cost-effectiveness ratio (ICER) for vaccination and screening compared with screening alone were estimated for each vaccination age. Reduced VE in women post-sexual debut were investigated in scenario analyses.

Results

With 70 % vaccination coverage, a reduction of cancer cases varying from 585 to 33 in rural and 691 to 32 in urban were estimated at ages 12 to 55, respectively. The discounted ICERs of vaccination at any age under 23 years in rural and any age under 25 years in urban were lower than the current threshold. Scenario analyses with lower VE post-sexual debut confirmed the results with age 20 in rural and 21 in urban had consistent lower ICERs. The more ‘catch-up’ cohorts vaccinated at the start of a program, the more cancer lesions are avoided in the long-term.

Conclusions

Vaccination at any age under 23 years old in rural and any age under 25 years old in urban were cost-effective. Catch-up to the age of 25 years in rural and urban could still be cost-effective.

Available only for authorised users

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer: Lyon, France; 2013. Available from: http://globocan.iarc.fr. Accessed on 26 Mar 2015.

The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. doi:10.1056/NEJMoa061741.CrossRef

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99. doi:10.1016/S1470-2045(11)70286-8.CrossRefPubMed

Bonanni P, Bechini A, Donato R, Capei R, Sacco C, Levi M, et al. Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines. 2015;3:3–12. doi:10.1177/2051013614557476.PubMedCentralCrossRefPubMed

NCT00779766. Available from: www.clinicaltrials.gov, accessed on 21 Dec 2015.

Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29:2487–94. doi:10.1016/j.vaccine.2010.12.085.CrossRefPubMed

Giraldi G, Martinoli L, De Luca d’Alessandro E. The human papillomavirus vaccination: a review of the cost-effectiveness studies. Clin Ter. 2014;165:e426–32. doi:10.7417/CT.2014.1787.PubMed

World Health Organization. Vaccine introduction guidelines: adding a vaccine to a national immunization programme. Decision and implementation: report no. WHO/IVB/05.18. Geneva: WHO; 2005.

World Health Organization. Human papillomavirus vaccines, WHO position paper. Wkly Epidemiol Rec. 2009;84:118–31.

10.

Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost- effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2011;56:153–62. doi:10.1007/s00038-010-0216-6.PubMedCentralCrossRefPubMed

11.

Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007;7:289–96. doi:10.1016/S1473-3099(07)70083-X.CrossRefPubMed

12.

Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine. 2008;26:6258–65. doi:10.1016/j.vaccine.2008.09.036.CrossRefPubMed

13.

Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics. 2009;27:127–47. doi:10.2165/00019053-200927020-00004.CrossRefPubMed

14.

Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infectious Diseases. 2009;9:119. doi:10.1186/1471-2334-9-119.PubMedCentralCrossRefPubMed

15.

Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16:217–30.PubMed

16.

Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine. 2008;26 Suppl 10:K76–86. doi:10.1016/j.vaccine.2008.06.009.PubMedCentralCrossRefPubMed

17.

Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20:385–92. doi:10.1111/IGC.0b013e3181d189b8.CrossRefPubMed

18.

National Bureau of Statistics of China. Available from: http://www.stats.gov.cn/tjsj/ndsj/2012/indexeh.htm, accessed on 24 Feb 2016.

19.

Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, et al. Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment. Zhonghua Zhong Liu Za Zhi. 2012;34:632–6. doi:10.3760/cma.j.issn.0253-3766.2012.08.017.PubMed

20.

Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modeling study. BMC Cancer. 2011;11:239. doi:10.1186/1471-2407-11-239.PubMedCentralCrossRefPubMed

21.

Shi JF, Chen JF, Canfell K, Feng XX, Ma JF, Zhang YZ, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Services Research. 2012;12:123. doi:10.1186/1472-6963-12-123.PubMedCentralCrossRefPubMed

22.

Liu YJ, Zhang Q, Hu SY, Zhao FH. Costs of detection and treatment of cervical cancer, cervical intraepithelial neoplasias in China. Beijing, China: Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN); 2014.

23.

Yu WZ, Yu JJ, Cui G, Jin SG, Wang J, Tao Z. Study on the Reasonable Cost of National Immunization Program in Some Regions of China. Chinese J of Vaccines and Immunization. 2006;4:280–84.

24.

Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high uptake of human papillomavirus vaccine in Cameroon: Lessons learned in overcoming challenges. Vaccine. 2014;32(35):4399–403. doi:10.1016/j.vaccine.2014.06.064.CrossRefPubMed

25.

Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995–3002. doi:10.1001/jama.285.23.2995.CrossRefPubMed

26.

Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762–75. doi:10.1093/aje/kwk059.CrossRefPubMed

27.

Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48. doi:10.3201/eid0901.020168.PubMedCentralCrossRefPubMed

28.

Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–35. doi:10.1016/S0029-7844(98)00245-2.CrossRefPubMed

29.

Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S43–103. http://dx.doi.org/10.1016/S0020-7292(06)60030-1.CrossRefPubMed

30.

Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160–71.CrossRefPubMed

31.

Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26 Suppl 5:F29–45. doi:10.1016/j.vaccine.2008.05.069.CrossRefPubMed

32.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15. doi:10.1093/jnci/djh104.CrossRefPubMed

33.

Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–92.CrossRefPubMed

34.

Trogdon JG, Ekwueme DU, Subramanian S, Crouse W. Economies of scale in federally-funded state-organized public health programs: results from the National Breast and Cervical Cancer Early Detection Programs. Health Care Manag Sci. 2014;17:321–30. doi:10.1007/s10729-013-9261-z.CrossRefPubMed

35.

Vale DB, Morais SS, Pimenta AL, Zeferino LC. Assessment of the cervical cancer screening in the Family Health Strategy in Amparo, Sao Paulo State, Brazil. Cad Saude Publica. 2010;26:383–90.CrossRefPubMed

36.

Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101. doi:10.1002/ijc.21955.CrossRefPubMed

37.

Cancer IAR. IARC Handbooks of Cancer Prevention Vol. 10. Cervix Cancer Screening. Lyon: IARC Press; 2005.

38.

WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in China. Summary Report 2010. Available from: http://www.hpvcentre.net/, accessed on 24 Feb 2016.

39.

Women’s health in rural China. Lancet 2009; 374:358. DOI: 10.1016/S0140-6736(09)61394-5.

40.

The 2010 Population Census of the Peoples Republic of China. Available from: http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm, accessed on 4 Jul 2014.

41.

Zhao FH, Tiggelaar SM, Hu SY, Xu LN, Hong Y, Niyazi M, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol. 2012;36:384–90. doi:10.1016/j.canep.2012.01.009.CrossRefPubMed

42.

Centers for Disease Control and Prevention (CDC). Progress in hepatitis B prevention through universal infant vaccination-China, 1997–2006. MMWR Morb Mortal Wkly Rep. 2007;56:441–5.

43.

WHO Commission on Macroeconomics and Health. Health Investing in Health for Economic Development. Geneva: WHO; 2001.

44.

World Health Organization, Initiative for Vaccine Research (IVR) of the Department of Immunization, Vaccines and Biologicals. WHO guide for standardization of economic evaluations of immunization programmes. Ordering code: WHO/IVB/08.14 Printed: December 2008.

45.

National Bureau of Statistics of China. Available from: http://www.stats.gov.cn/tjsj/ndsj/2013/indexeh.htm, accessed on 24 Feb 2016.

46.

Chen WQ, Zhang SW, Zeng HM, Zheng RS, Zou XN, Zhao P, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2(7):61.PubMedCentralPubMed

47.

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1–K16.CrossRefPubMed

48.

Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012;131(12):2929–38. doi:10.1002/ijc.27571.PubMedCentralCrossRefPubMed

49.

de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.CrossRefPubMed

50.

Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1808–16.CrossRefPubMed

51.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3 Suppl):S15–23. doi:10.1016/j.ygyno.2009.09.021.CrossRefPubMed

52.

Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine. 2009;27(4):581–7. doi:10.1016/j.vaccine.2008.10.088.CrossRefPubMed

53.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26:4080–93. doi:10.1016/j.vaccine.2008.04.053.CrossRefPubMed

54.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomaviru (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5:705–19. doi:10.4161/hv.5.10.9518.CrossRefPubMed

55.

Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine. 2012;30 Suppl 5:F139–48. doi:10.1016/j.vaccine.2012.05.039.CrossRefPubMed

56.

Favato G, Pieri V, Mills R. Cost/Effective Analysis of Anti-HPV Vaccination Programme in Italy: A Multi-Cohort Markov Model. Ssrn Electronic Journal, 2007. Available from: http://dx.doi.org/10.2139/ssrn.961847.

57.

Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821–32. doi:10.1056/NEJMsa0707052.PubMedCentralCrossRefPubMed

58.

Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769. doi:10.1136/bmj.a769.PubMedCentralCrossRefPubMed

59.

Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151:538–45. doi:10.7326/0003-4819-151-8-200910200-00007.PubMedCentralCrossRefPubMed

60.

Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-eff ectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406–14. doi:10.1016/S2214-109X(14)70237-2.CrossRefPubMed

61.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10. doi:10.1016/S1470-2045(11)70287-X.CrossRefPubMed

62.

Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, et al. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer. 2012;131(12):2832–8. doi:10.1002/ijc.27586.CrossRefPubMed

63.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–9.CrossRefPubMed

64.

Gaudet M, Hamm J, Aquino-Parsons C. Incidence of ano-genital and head and neck malignancies in women with a previous diagnosis of cervical intraepithelial neoplasia. Gynecol Oncol. 2014;134:523–6. doi:10.1016/j.ygyno.2014.07.088.CrossRefPubMed

65.

Sathish N, Wang X, Yuan Y. Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies. J Dent Res. 2014;93:29S–36S. doi:10.1177/0022034514527969.PubMedCentralCrossRefPubMed

66.

Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One. 2014;9:e88323. doi:10.1371/journal.pone.0088323.PubMedCentralCrossRefPubMed

Title: Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
Authors: Yi-Jun Liu
Qian Zhang
Shang-Ying Hu
Fang-Hui Zhao
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-016-2207-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma

Prospective study of postoperative whole breast radiotherapy for Japanese large-breasted women: a clinical and dosimetric comparisons between supine and prone positions and a dose measurement using a breast phantom

The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study

Both Talin-1 and Talin-2 correlate with malignancy potential of the human hepatocellular carcinoma MHCC-97 L cell

Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer